Effects of Moderate Physical Activity on Glycemic Control in Type 2 Diabetes Mellitus

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04924777

Enrollment

Registered

2021-06-14

Start date

2021-04-01

Completion date

2021-07-31

Last updated

2021-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

The study design is to determine the effectiveness of moderate physical activity on g;lycemic control in type 2 diabetes mellitus.

Detailed description

To the best of authors knowledge so far the studies have been conducted on different modes of moderate physical activity on glycemic control in type 2 diabetes, current study goal is to evaluate which mode of moderate physical activity has more significant result on glycemic control in type 2 diabetes and is sustainable in Pakistani society according to the socioeconomic status and cost effectiveness of the modes of moderate physical activity.

Interventions

OTHERBrisk Walk

1-Brisk walk for 30 minutes 2-5 days a week 3-3months

OTHERStrength training

1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months

OTHERAerobic Exercises

1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Participants falling in this category would be recruited into the study. * Male/female * Diabetic type 2 patients * Age: 30-70 years * BMI \>25 * Overweight * Fat % in male\> 25 * Fat % in female \>35 * HbA1c level more than 48mmol/mol or \>6.5% * Fasting Plasma Glucose level \>126 mg/dl (7.0 mmol/l) * Random Plasma glucose level \>200 mg/dl (11.1 mmol/l) * Physically active ( have no mobility problems)

Exclusion criteria

* Participant failing to fall in this category would be excluded of the study. * Type 1 diabetes * Insulin dependant type 2 diabetes * Gestational Diabetes * Hypertension * Cigarette smoking * Cardiovascular Disease * Cerebrovascular disease * Cardiopulmonary Disorders * Cognition Problems * Peripheral Artery Disease * Dyslipidemia * Proliferative or preproliferative retinopathy * Nephropathy * Neuropathy

Design outcomes

Primary

Measure	Time frame	Description
HbA1c Levels	3 months	Reduction in HbA1c levels

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026